| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Malignant gliomas are among the most common types of brain tumor, and the prognosis remains extremely poor. Oncolytic viral therapy is expected as a new treatment modality for malignant glioma. In this study, we tried to produce a new oncolytic virus with powerful effect for glioma therapy by passaging virus in vivo instead of genetically engineering. Passaged viruses are not more toxic, and it suggests that passaged viruses could be more effective for glioma therapy than parent strains. We intend to continue this study to accumulate data.
|
